Key Highlights

  • Shareholders approved a $25.00 per share cash acquisition. Next catalyst: Merger anticipated to finalize swiftly.
  • An estimated 99.75% of votes cast at the special meeting supported the American Industrial Partners acquisition.
  • Avanos stockholders are set to receive $25.00 for each share of their common stock.

Avanos Medical, Inc. (NYSE: AVNS) shareholders have overwhelmingly approved the proposed acquisition of the medical technology company by investment funds affiliated with American Industrial Partners (AIP). The decisive vote paves the way for Avanos stockholders to obtain $25.00 per share in cash as the transaction progresses toward its anticipated conclusion. This strategic move highlights the ongoing consolidation within the medical technology sector, where specialized companies often seek partnerships to accelerate growth and innovation.

The strong shareholder mandate reflects confidence in the strategic direction and the value offered by the cash acquisition.

Shareholder Green Light for AIP Acquisition

The special meeting of Avanos stockholders saw a strong turnout and a clear decision regarding the merger agreement. Preliminary voting results indicated that an estimated 99.75% of votes cast at the meeting were in favor of the transaction. This figure accounted for approximately 74.96% of the entire outstanding Avanos common stock as of the record date.

A quorum was established at the meeting, with a total of 35,207,549 shares, or approximately 75.15% of the 46,847,816 outstanding common shares, present in person or by proxy. The strong approval margin signals widespread agreement among investors that the merger offers a compelling path forward for Avanos Medical. The transaction involves A-AV Holdco I, Inc.

as the parent entity and A-AV MergerSub, Inc. a wholly-owned subsidiary of Parent, merging with Avanos, which will then become a wholly-owned subsidiary of Parent. This cash offer represents a significant valuation for the company's assets and future prospects, common in private equity acquisitions within the medical technology space. Such fixed cash payouts provide a definite exit value, effectively locking in gains for investors who might otherwise face the uncertainties of continued market volatility.

Market Performance and Strategic Rationale

Avanos Medical shares have demonstrated significant upward momentum leading up to this acquisition, reflecting investor optimism. The acquisition price of $25.00 per share provides shareholders with a compelling valuation for their holdings. Gary D.

Blackford, Avanos' Board chair, expressed satisfaction with the outcome, highlighting the anticipated benefits of partnering with AIP, including enhanced flexibility and resources to better address evolving healthcare needs. This partnership allows Avanos to pursue long-term strategic initiatives and invest in innovation without the short-term pressures often associated with public market scrutiny, a common rationale for such transactions in the medical technology industry. The favorable market conditions preceding the offer likely contributed to shareholders' willingness to accept a definitive cash offer.

With the primary conditions now satisfied, the transaction is on track to close swiftly. A non-binding, advisory proposal concerning compensation for named executive officers related to the merger was also approved by stockholders. With all major hurdles cleared, the focus now shifts entirely to the timely execution of the final transaction.

Based on the regulatory filing by AVANOS MEDICAL, INC. On 22 July 2026.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.